[
    [
        {
            "time": "2018-07-01",
            "original_text": "Insurance tactic drags down U.S. drug prices in 2nd qtr -analyst",
            "features": {
                "keywords": [
                    "Insurance",
                    "tactic",
                    "drags",
                    "down",
                    "U.S.",
                    "drug",
                    "prices"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Insurance tactic drags down U.S. drug prices in 2nd qtr -analyst",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-07-02",
            "original_text": "Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)",
            "features": {
                "keywords": [
                    "Novo",
                    "Nordisk",
                    "Ozempic",
                    "Lowers",
                    "Risk",
                    "Cardiovascular",
                    "Events"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-03",
            "original_text": "Insurance tactic drags down U.S. drug prices in 2nd quarter -analyst",
            "features": {
                "keywords": [
                    "Insurance",
                    "tactic",
                    "drags",
                    "down",
                    "U.S.",
                    "drug",
                    "prices"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Insurance tactic drags down U.S. drug prices in 2nd quarter -analyst",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-07-04",
            "original_text": "AstraZeneca Up This Year So Far on Favorable Pipeline Updates",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "Up",
                    "Favorable",
                    "Pipeline",
                    "Updates"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AstraZeneca Up This Year So Far on Favorable Pipeline Updates",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-07-05",
            "original_text": "Better Buy: Pfizer Inc. vs. Eli Lilly and Company",
            "features": {
                "keywords": [
                    "Better",
                    "Buy",
                    "Pfizer",
                    "Eli",
                    "Lilly"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Better Buy: Pfizer Inc. vs. Eli Lilly and Company",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-07-06",
            "original_text": "WisdomTree U.S. LargeCap Dividend Fund -- Insider Buying Index Registering 12.1%",
            "features": {
                "keywords": [
                    "WisdomTree",
                    "U.S.",
                    "LargeCap",
                    "Dividend",
                    "Fund",
                    "Insider",
                    "Buying",
                    "Index"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "dividends"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "WisdomTree U.S. LargeCap Dividend Fund -- Insider Buying Index Registering 12.1%",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-07-07",
            "original_text": "How Eli Lilly’s Elanco Performed in Q2 2018",
            "features": {
                "keywords": [
                    "Eli",
                    "Lilly",
                    "Elanco",
                    "Performed",
                    "Q2",
                    "2018"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "How Eli Lilly’s Elanco Performed in Q2 2018",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-07-08",
            "original_text": "A Look at Eli Lilly’s Neuroscience Products in Q2 2018",
            "features": {
                "keywords": [
                    "Eli",
                    "Lilly",
                    "Neuroscience",
                    "Products",
                    "Q2",
                    "2018"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A Look at Eli Lilly’s Neuroscience Products in Q2 2018",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        }
    ]
]